Eligibility
Applicant type, geography, program rules and required conditions.
My Organization Fit Score
See how strongly this opportunity fits your organization.
Atlas combines public grant intelligence with the details of your organization to evaluate eligibility, strategic alignment, funding potential, timing, project fit and submission burden.
GrantNIH NINDS Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (PAR-25-024)
Atlas Opportunity Score98/100
FundingApplication budgets are not limited but must reflect actual project needs; R61 1-3 years plus R33 1-3 years, maximum combined project period 5 years.
DeadlineOctober 20, 2026 at 5:00 PM local time of the applicant organization. Additional listed receipt dates continue in 2027; expiration January 8, 2028.
Required next actionApplicant research teams should define the candidate or composite biomarker and Context of Use, assemble the required human data or sample strategy, specify detection-method performance and quantitative R61-to-R33 Go or No-Go milestones, and submit by October 20, 2026 at 5:00 PM local time of the applicant organization for the current cycle.
Current statusOpenSource verificationOctober 5, 2026
Tell Atlas Who You Are
Request your organization-specific analysis.
The form will carry the grant context with it, so you only need to provide the details Atlas cannot know from the opportunity itself.
How Atlas Scores Fit
Useful enough to guide action, structured enough to scale.
Strategic Alignment
How directly the organization's goals and use case match the funder's priorities.
Funding Potential
Available dollars, allowable uses, match burden and the amount that can realistically support the project.
Actionability
Deadline, documentation burden, readiness and the practical work required to submit a strong application.
A High Score Is the Beginning
When the fit is strong, Atlas shows you why.
The goal is not to hand you another number. It is to identify the opportunities worth your attention and make the next step obvious.